1. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1278,
2001,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
2. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1278,
2001,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
3. |
Celecoxib: low cost alternative in OA and RA |
|
Inpharma Weekly,
Volume &NA;,
Issue 1278,
2001,
Page 4-5
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
4. |
Low-cost alternative schedule for pre-exposure rabies vaccination |
|
Inpharma Weekly,
Volume &NA;,
Issue 1278,
2001,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
5. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1278,
2001,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
6. |
Rofecoxib: potential in colorectal cancer prevention? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1278,
2001,
Page 7-7
Ed Susman,
Preview
|
|
摘要:
Rofecoxib, a cyclo-oxygenase (COX)-2 inhibitor used extensively for the treatment of osteoarthritis, may one day prevent colon polyps that precede colorectal cancer, say researchers from Merck. In an animal study presented recently at the annual meeting of the American Association for the Advancement of Science [San Francisco, US; February 2001], the drug dramatically reduced the number of polyps that are associated with the later emergence of colorectal cancer, said Dr Jillian Evans, director of pharmacology at Merck Research Laboratories, West Point, Pennsylvania, US.'I'm a basic scientist and this is an animal model, but we are hopeful that this[rofecoxib]might translate into a chemopreventive in humans',Dr Evans said.
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
7. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1278,
2001,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
8. |
Triple therapy including once-daily emtricitabine effective in HIV |
|
Inpharma Weekly,
Volume &NA;,
Issue 1278,
2001,
Page 9-10
Carmen Innes,
Preview
|
|
摘要:
Once-daily emtricitabine ['Coviracil'] is effective and well tolerated in patients with HIV infection, say researchers from Triangle Pharmaceuticals. Data were recently presented from studies FTC-302 and FTC-303, which compared triple therapy regimens containing once-daily emtricitabine or twice-daily lamivudine, and from a French study which evaluated the effectiveness of a once-daily regimen of emtricitabine, didanosine and efavirenz. The studies were presented at the 8th Conference on Retroviruses and Opportunistic Infections [Chicago, US; February 2001].
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
9. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1278,
2001,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
10. |
Pravastatin reduces risk of developing diabetes mellitus? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1278,
2001,
Page 11-11
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|